AbCellera Biologics Inc.

AbCellera Biologics reported a net loss of $(55.4) million for Q2 2026, widening from $(34.7) million in Q2 2025, while total revenue decreased significantly to $4.1 million from $17.1 million year-over-year. For the first six months of 2026, the net loss was $(98.6) million on $12.4 million in revenue. The company also announced new collaboration agreements, including a $56.0 million upfront payment from Jazz Pharmaceuticals in June 2026 and a $28.0 million upfront payment from Vertex Pharmaceuticals in July 2026, for multispecific antibody development.

AbCellera reported a Q2 2026 net loss of $55.4 million, or $(0.18) per share, on revenue of $4.1 million, a significant decrease from Q2 2025. Despite the financial decline, the company announced two new collaborations with Jazz Pharmaceuticals and Vertex Pharmaceuticals, securing $112 million in total upfront payments. These partnerships leverage AbCellera's T-cell engager platform for oncology and autoimmune diseases, with potential for substantial future milestone payments and royalties. The company maintains over $675 million in total available liquidity.

AbCellera Biologics Inc. announced the appointment of Lynn Seely, M.D. to its Board of Directors as a new independent Class III director. Dr. Seely will serve until the 2029 annual meeting and will be compensated under the Non-Employee Director Compensation Policy. Her extensive background includes leadership roles at Lyell Immunopharma, Myovant Sciences, and Medivation, bringing significant experience in biopharmaceutical development and commercialization to AbCellera's board.

AbCellera Biologics Inc. announced a preclinical research collaboration, option, and license agreement with Jazz Pharmaceuticals. The partnership aims to discover and develop next-generation T-cell engaging multispecific antibodies for various gastrointestinal cancers and other solid tumors, leveraging AbCellera's antibody discovery engine. AbCellera will receive $56 million in upfront payments for the initial two programs, with an additional $28 million upon starting a third program. The agreement also includes potential option fees and milestone payments of up to $792 million per program, plus tiered royalties on net sales.

AbCellera Biologics Inc. announced the appointment of Dr. Victor Sandor to its Board of Directors as an independent director, effective June 1, 2026. Dr. Sandor brings extensive experience as a medical oncologist and in building companies, having held key leadership roles at Array BioPharma Inc. and Incyte Corporation where he contributed to the approval of several innovative medicines. He will serve until the company's next annual meeting and will be compensated under the existing non-employee director policy.

AbCellera Biologics Inc. reported its first-quarter 2026 financial results, showing an increase in total revenue to $8.32 million, up from $4.24 million in the prior year's quarter. The company also saw an improvement in its net loss, which narrowed to $(43.17) million from $(45.62) million year-over-year. Despite the revenue growth and reduced net loss, cash and cash equivalents decreased, and net cash used in operating activities significantly increased, reflecting ongoing investment in research and development as a clinical-stage biotechnology company.

AbCellera Biologics Inc. announced its Q1 2026 financial and operational results, reporting a net loss of $43.2 million, an improvement from $45.6 million in Q1 2025, and revenue of $8.3 million, up from $4.2 million. The company also released positive interim Phase 1 data for ABCL635, its antibody for vasomotor symptoms, highlighting a favorable tolerability profile, potential for once-monthly dosing, and strong target engagement. AbCellera ended the quarter with approximately $655 million in total available liquidity to execute its strategy.

AbCellera Biologics Inc. announced its 2026 Annual Meeting of Shareholders will be held virtually on June 11, 2026. Shareholders will vote on the election of two Class III directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026, and a non-binding advisory vote on named executive officer compensation. The company previously dismissed KPMG LLP and engaged Ernst & Young LLP on November 28, 2025. Additionally, Stephen R. Quake was appointed to the Board in November 2025 following Andrew Lo's retirement.